SimpleFunctions
Winner-take-all answer·15 source contracts·Kalshi 15·refreshed just now·Closes Dec 31, 2026 · 172d

What will Johnson & Johnson say during their next earnings call

Leader sits at 84% across 15 bound outcomes, runner-up at 83%. This is a winner-take-all market — the headline is the leader’s price, not an arithmetic mean.

Leader probability

84%

Ottava

runner-up 83¢leader 84¢

Outcomes

15

winner-take-all

Runner-up

83¢

Procedure

Spread

1pp

contested

24h volume

$557

thin orderbook

Closes

Dec 31, 2026

172 days

Venue

Kalshi

15 bound

30-day trend

0%50%100%-30d-3w-2w-1wtodayOttava: 80% (10 days, 10 points)Ottava: 80% on 2026-07-11Procedure: 59% (10 days, 9 points)Procedure: 59% on 2026-07-11Europe: 78% (10 days, 10 points)Europe: 78% on 2026-07-11
Ottava80¢Procedure59¢Europe78¢
Top 3 candidates by current price · 10d

Bracket family

How the bracket ladder is priced.

Each row is one outcome on the venue. Sorted by 24h volume — the heaviest book is at the top.

Cluster 1

What will Johnson & Johnson say during their next earnings call

15 contracts$557
OutcomePrice24hVolumeVenueDetail

What will Johnson & Johnson say during their next earnings call?: Nipocalimab / Lupus

KXEARNINGSMENTIONJNJ-26JUL15-NIPO

48¢1pp$275K

What will Johnson & Johnson say during their next earnings call?: AI / Artificial Intelligence

KXEARNINGSMENTIONJNJ-26JUL15-AI

27¢1pp$184K

What will Johnson & Johnson say during their next earnings call?: China

KXEARNINGSMENTIONJNJ-26JUL15-CHIN

72¢+12pp$31K

What will Johnson & Johnson say during their next earnings call?: Europe

KXEARNINGSMENTIONJNJ-26JUL15-EURO

79¢1pp$28K

What will Johnson & Johnson say during their next earnings call?: Darzalex Faspro

KXEARNINGSMENTIONJNJ-26JUL15-DARZ

51¢+2pp$13K

What will Johnson & Johnson say during their next earnings call?: Procedure

KXEARNINGSMENTIONJNJ-26JUL15-PROC

83¢+14pp$9K

What will Johnson & Johnson say during their next earnings call?: Ottava

KXEARNINGSMENTIONJNJ-26JUL15-OTTA

84¢+5pp$6K

What will Johnson & Johnson say during their next earnings call?: Litigation

KXEARNINGSMENTIONJNJ-26JUL15-LITI

44¢+2pp$5K

What will Johnson & Johnson say during their next earnings call?: Administration

KXEARNINGSMENTIONJNJ-26JUL15-ADMI

41¢+3pp$5K

What will Johnson & Johnson say during their next earnings call?: Tariff

KXEARNINGSMENTIONJNJ-26JUL15-TARI

66¢+8pp$1K

What will Johnson & Johnson say during their next earnings call?: Vaccine

KXEARNINGSMENTIONJNJ-26JUL15-VACC

7¢2pp$0K

What will Johnson & Johnson say during their next earnings call?: Trufill

KXEARNINGSMENTIONJNJ-26JUL15-TRUF

6¢+2pp$0K

What will Johnson & Johnson say during their next earnings call?: Rybrevant

KXEARNINGSMENTIONJNJ-26JUL15-RYBR

54¢+3pp$0K

What will Johnson & Johnson say during their next earnings call?: Halda Therapeutics

KXEARNINGSMENTIONJNJ-26JUL15-HALD

33¢±0$0K

What will Johnson & Johnson say during their next earnings call?: Gene Therapy

KXEARNINGSMENTIONJNJ-26JUL15-GENE

7¢+1pp$0K

Analysis

This market predicts that Johnson & Johnson will mention Ottava during their next earnings call, with a leading probability of 84%. The high confidence reflects Ottava's recent acquisition and clinical significance to J&J's portfolio, as this is a natural topic for management to discuss with investors. The probability could shift based on the timing of the earnings call relative to Ottava developments, competitive announcements, or changes in J&J's communication strategy. The next scheduled earnings call will definitively resolve this outcome by either including or excluding Ottava discussion. Movements would likely follow clinical trial updates, regulatory decisions affecting Ottava, or shifts in management's prioritization of this asset relative to other pipeline programs like Darzalex Faspro or Halda Therapeutics.

  • J&J's recent acquisition of Ottava and its strategic importance to the company's robotics and surgical platforms
  • Historical pattern of J&J mentioning major recent acquisitions and pipeline assets during earnings calls to investors
  • Trading volume concentration on Ottava contract ($300 24h volume) versus Vaccine, Darzalex Faspro, and AI contracts, indicating market confidence in this outcome
  • Timing of next earnings call relative to any Ottava clinical, regulatory, or commercial milestones
  • Management's typical communication frequency regarding surgical innovation and robotics segments during investor presentations

What moved the line

  • Jul 9China33pp7239¢ · Kalshi
  • Jul 6Procedure31pp2859¢ · Kalshi
  • Jul 7Tariff27pp2956¢ · Kalshi
  • Jul 9Nipocalimab / Lupus17pp4730¢ · Kalshi
  • Jul 10Procedure15pp6045¢ · Kalshi

Recently closed in general

These markets stopped trading. Last odds and any captured outcome are shown above — full settlement detail lives at the venue.

More like this

Adjacent prediction questions.

How we compute these odds

SimpleFunctions aggregates live prediction-market contracts from Kalshi and Polymarket. Each slug groups contracts that resolve on the same underlying event, identified by venue event_id.

For binary slugs, the headline probability is the liquidity-weighted mid-price across all bound contracts. For multi-outcome slugs (e.g. elections with 3+ candidates), the headline is the leader’s price; we never arithmetically average disjoint outcomes — that would produce a number with no real-world meaning.

Snapshots refresh every 5 minutes during market hours; daily aggregates are computed at 04:00 UTC. The 30-day sparkline is drawn from per-ticker daily means stored in market_indicator_daily; 24h delta and movement events are derived from the same source.

Last updated on this page: just now.